3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
5
Thoracic
1
Sarcoma
1
Head & Neck
1
Conditions
Sarcoma
25
Central Nervous System Neoplasms
18
Astrocytoma
15
Gliosarcoma
14
Glioblastoma
14
Ovarian Neoplasms
12
Oligodendroglioma
10
Neuroectodermal Tumors, Primitive, Peripheral
10
Brain Neoplasms
10
Osteosarcoma
9
Neuroblastoma
9
Testicular Neoplasms
8
Glioma
8
Dendritic Cell Sarcoma, Interdigitating
8
Medulloblastoma
7
Breast Neoplasms
7
Choroid Plexus Neoplasms
6
Carcinosarcoma
6
Burkitt Lymphoma
6
Wilms Tumor
5
Testicular Germ Cell Tumor
5
Stomach Neoplasms
5
Rhabdoid Tumor
5
Optic Nerve Glioma
5
Neoplasms
5
Lymphoma, Non-Hodgkin
5
Lymphoma, Large B-Cell, Diffuse
5
Kidney Neoplasms
5
Head and Neck Neoplasms
5
Retinoblastoma
4
Interventions
Standard of Care
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
sarilumab
1
regorafenib
1
pexidartinib
1
pertuzumab
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
durvalumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Trastuzumab
1
Transurethral Resection of Bladder
1
STA 9090
1
SGN-LIV1A
1
Paclitaxel
1
MK 2206
1
Letrozole
1
Lasofoxifene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Carboplatin
×
Sarcoma
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled